Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|SY-1365||SY1365||CDK7 Inhibitor 13||SY-1365 is a selective CDK7 inhibitor that induces apoptosis in tumor cells (PMID: 31064851, PMID: 32150405).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||SY-1365||Preclinical - Cell culture||Actionable||In a preclinical study, SY-1365 induced rapid apoptosis in a panel of solid tumor cell lines in culture, including breast, ovarian, colorectal, and lung cancer cells (Proceedings of the AACR, Vol 58, April 2017, Abstract # 1151).||detail...|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||SY-1365||Preclinical - Pdx & cell culture||Actionable||In a preclinical study, SY-1365 induced rapid apoptosis in triple-receptor negative breast cancer cells in culture, and resulted in tumor growth inhibition in patient-derived xenograft models (Proceedings of the AACR, Vol 58, April 2017, Abstract # 1151).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03134638||Phase I||Carboplatin + SY-1365 SY-1365 Fulvestrant + SY-1365||A Study of SY-1365 in Adult Patients With Advanced Solid Tumors||Active, not recruiting|